The abbreviations used are: MBD, methyl-CpG binding domain; MBD3L2, methyl-CpG-binding protein 3-like-2; GST, glutathione-S-transferase; GFP, green fluorescent protein; ChIP, chromatin immunoprecipitation. 
INTRODUCTION
DNA methylation has the capacity to inhibit gene expression through proteins that can bind specifically to methylated CpG sequences in critical regulatory sequences (1-3). The prototype methyl-CpG-binding protein is MeCP2, a polypeptide capable of binding selectively to a single symmetrically methylated CpG sequence (4, 5) . MeCP2 is physically associated with the transcriptional corepressor Sin3 and histone deacetylases in both mammalian cells and Xenopus oocytes (6, 7) . This suggests that MeCP2 may play a role in the assembly of a specialized chromatin structure at methylated CpG sequences. Recruitment of MeCP2 to a promoter leads to transcriptional repression that can be partially relieved by inhibitors of histone deacetylases (6, 7) . In 1998, four additional genes, which encode methyl-CpG-binding domain (MBD) proteins, were identified (8) . These proteins were named MBD1, MBD2, MBD3, and MBD4. The five MBD-containing proteins (MBD1-4 and MeCP2) are most similar within their MBD domains (1-3). In fact, the similarity is very limited outside of the MBD with the exception of MBD2 and MBD3, which share >65% identity over most of the length of the entire MBD3 protein. Expression studies indicated that these MBD proteins are expressed in all tissues analyzed. MBD4 is a G/T mismatchspecific DNA glycosylase functioning in DNA repair by removing deaminated 5-methylcytosine bases from DNA (9) .
MeCP2, MBD1, MBD2, and MBD3 are involved in gene silencing imposed by methylated DNA (6, 7, (10) (11) (12) (13) (14) (15) (16) . MBD2 is highly similar to MBD3 in a region corresponding to amino acids 140-400 (8) . However, the M B D 2 mRNA codes for an additional N-terminal 140 amino acids, which is not found in MBD3. This region of MBD2 contains a glycine arginine-rich repeat region of unknown function (Fig. 1 ). There are two translated protein products of the MBD2 mRNA: MBD2a and MBD2b. MBD2b is a shorter version of MBD2a lacking the amino terminal 140 amino acids due to usage of a different start codon. The recombinant MBD2b protein has been reported to possess DNA demethylase activity (17) , although this finding has so far not been repeated in other laboratories (11, 16, 18) .
3 cotransfection experiments, MBD2b increased transcriptional repression with methylated reporter constructs (16) . There is evidence showing that MBD2 is the methyl CpG binding component of a larger complex named MeCP1, a methylated DNA binding complex identified a decade earlier (11, 19, 20) . While MBD2 is associated with HDAC1 and with RbAp48/RbAp46 by coimmunoprecipitation analysis, it is not a direct component of the previously defined Sin3 and Mi-2/NuRD complexes (but see below).
The coding sequence of MBD3 is highly similar to that of MBD2 throughout its entire length (8) . MBD3 mRNA is widely expressed in most mouse and human tissues. There are several splice variants of MBD3 including some, which have a disrupted MBD domain. All mammalian splice variants of MBD3 fail to bind to methylated DNA in vitro (8, 18, 20, 21) . This suggests that MBD3 may possess at least some functions that are independent of DNA methylation. However, Xenopus and zebrafish MBD3 proteins can bind to methylated DNA, presumably due to an amino acid difference in the MBD domain (1). Interestingly, both zebrafish (22) and Xenopus (23) lack the global demethylation event characteristic of early mammalian development (24) .
NuRD/Mi-2 is a multisubunit complex containing nucleosome remodeling and histone deacetylase activities (25) (26) (27) (28) . The histone deacetylases HDAC1 and HDAC2 and the histone binding proteins RbAp46 and RbAp48 form a core complex shared between NuRD and Sin3-histone deacetylase complexes. MBD3 was found to be a subunit of the NuRD complex (20, 21, 26) . A protein called MTA2 modulates the enzymatic activity of the histone deacetylase core complex. MBD3 mediates the association of MTA2 with the core histone deacetylase complex. The MeCP1 complex contains ten major polypeptides including MBD2 and all of the known NuRD components (29) . Thus, NuRD may provide an important link between gene silencing and DNA methylation. The MBD3-containing NuRD complex in mammals can be targeted to methylated DNA by MBD2 (29) . In other words, MBD2 may interact with the NuRD complex and direct the complex to methylated DNA.
Recently we have identified and cloned MBD3L1 and MBD3L2, two proteins with substantial homology to MBD2 and MBD3 (30) . While MBD3L1 is expressed predominantly in round spermatids, expression of MBD3L2 is seen in many different tissue types. Given their homology with MBD3/MBD2, it is likely that these new proteins may also play an important role in transcriptional gene silencing or regulation of silencing. Here we have characterized the biological function of MBD3L2.
MATERIALS AND METHODS
Cell culture and transfection AD293, HeLa, NIH3T3 and COS7 cells were obtained from the American Type Culture Collection and were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum at 37°C in a 5% CO 2 standard incubator. DNA transfections were carried out in Opti-MEM-I medium (Invitrogen) using Lipofectamin or LipofectaminPlus reagent (Invitrogen) according to the manufacturer's instructions.
Cloning of human MBD3L2
A search of the human EST database using the amino acid sequences of MBD2 and MBD3 as a query revealed several human EST clones, including clone BE281376. The full-length cDNA for MBD3L2 was PCR-amplified from BE281376 and from human embryonal carcinoma cell lines (NT2 and PA1) by reverse transcription-PCR (RT-PCR) (30) .
Plasmids
For the yeast two-hybrid system, the cDNA fragments of MBD2a, MBD2b, MBD2t, MBD3 and MBD3L2 were subcloned into the BamHIEcoRI sites of pAS2-1 (baits) and pACT2 (preys) (Clontech). For the expression of recombinant proteins in E. coli, the cDNAs of MBD2b and MBD3 were subcloned in frame into the BamHISalI and BamH I -HindIII sites of pET-28a(+) (Novagen), respectively. The Flag-tagged MBD3L2 construct was made by insertion of the cDNA of MBD3L2 into the EcoRI-BglII sites of pT7-FLAG (Sigma). The cDNAs encoding MBD3 or its deletion constructs (amino acids 1 to 80, 1 to 4 150, 1 to 220, 1 to 260, 60 to 120 and 81 to 291) and MBD3L2 or its deletion constructs (amino acids 1 to 89, 1 to 115, 1 to 172 and 90 to 204) were cloned into the EcoRI-XhoI sites of pGEX-5X-1 (Amersham Biosciences) for GST pull-down assays. For the mammalian expression vectors, myc-tagged constructs were generated by insertion of the cDNAs of MBD2a, MBD2b, MBD3 and MBD3L2 into pCMV-Tag1 (Stratagene). The GFP-MBD3L2 construct was made by inserting the cDNA of MBD3L2 into the EcoRI-BamHI sites of pEGFP-N2 (Promega). In this construct the GFP moiety is on the N-terminus but a Cterminal-GFP-tagged protein showed identical localization patterns. Constructs fused to the GAL4 DNA binding domain were generated by inserting the cDNAs of full-length MBD3L2, MBD2b or MBD3 into the BamHI-KpnI sites, or the N-terminal portion (amino acids 1 to 72), the central portion (amino acids 70 to 135) or the Cterminal portion (amino acids 134 to 204) of MBD3L2 into the BamHI-EcoRI sites of pFA-CMV (Stratagene). All recombinant clones were verified by DNA sequencing.
Northern blot and RT-PCR
Northern blot was performed as previously described (30) . Human multiple tissue poly(A+) Northern blots were purchased from Clontech (Palo Alto, CA). The membranes were hybridized with a 245 bp probe made with primers MBD3L2-U 2 5
( 5'-GTGGGGTCAGCAGGAGGA-ACTCTACA) and MBD3L2-L270 (5'-TGACCTGGTTGTCAGGATGAGACCTG).
Yeast two-hybrid assays
Yeast two-hybrid assays were performed with the Matchmaker Two-Hybrid System 2 according to the manufacturer's instructions (Clontech). GAL4-DNA-binding domain fusions (baits) in the pAS2-1 plasmid and GAL4-activation domain fusions (preys) in the pACT2 plasmid were expressed in the PJ69-4A yeast strain, and the transformants were cultured on synthetic dropout (SD)-Ade-HisLeu-Trp plates.
Luciferase assays
The luciferase assays were performed as previously described (30) . On the day before transfection, 2.5 x 10 5 AD293 cells were seeded per well in 24-well plates and transfected with luciferase reporter (alpha-globin promoter, pG5--Luc or pG0--Luc; VHL promoter, pG6-VHLLuc or pG0-VHL-Luc), and effectors containing the GAL4 DNA binding domain and an internal control reporter for renilla luciferase expression (pRL-TK). At 48 h after transfection, cells were harvested and luciferase activity was detected using the dual luciferase assay system (Promega; Madison, WI). For trichostatin A (TSA) (Cell Signaling) treatment, TSA was added to the culture medium (final concentration 100 ng/ml) 24 hours after transfection, and cells were harvested after an additional 24 hours of incubation. Values are the means with standard deviations of the results obtained from three independent experiments.
GST pull-down assays GST protein or GST fusion proteins of MBD3L2 in the pEBG expression vector were expressed in AD293 cells. Forty-eight hours after transfection, whole cell extracts were prepared with lysis buffer containing 50mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Triton X-100, 200 mM sucrose and protease inhibitors (Roche Applied Science) and adsorbed onto glutathione sepharose 4B (Amersham Biosciences). After washing with lysis buffer, the bound proteins were eluted by boiling in SDS gel loading buffer and were fractionated on 10% SDS-polyacrylamide gels. The interacting proteins were analyzed by Western blotting using antibodies against components of the Mi-2/NuRD complex. Anti-Mi2 (1:500) and anti-p66 (1:600) antibodies were purchased from Upstate Biotechnology. Antibodies directed against HDAC1 (H-51, 1:1,000), HDAC2 (H-54, 1:800) mSin3A (AK-11, 1:1,000), MTA1 (A18, 1:800), RbAp46 (N-19, 1:1,000) and RbAp48 (N-19, 1:800) were purchased from Santa Cruz Biotechnology. Anti-MBD2a (1:1,000) was from Abcam. Anti-MBD3 (1:1,000) was a gift from Fuyuki Ishikawa (Kyoto University). Anti-Mi2 (1:1,000) was a gift from Paul Wade (Emory University).
In vitro binding assays
Bacterially expressed GST and GST fusion proteins (2 g) were immobilized on glutathioneagarose beads and incubated with His-or FLAGtagged proteins (2 g) in a binding buffer containing 0.1% Triton X-100, 50 mM HEPES, 5 pH 7.4, 250 mM NaCl, 5% glycerol, 2 mM dithiothreitol, 1 mg/ml bovine serum albumin, and protease inhibitors for 90 min at 4°C. The beads were washed three times with binding buffer. The bound proteins were eluted with SDS gel loading buffer, fractionated on 12% SDS-polyacrylamide gels and transferred onto nylon membranes. The membranes were incubated with mouse monoclonal anti-His antibody (1: 1500) (Amersham Biosciences) or anti-FLAG antibody (1: 1,500) (Stratagene) in blocking buffer, and washed three times with PBS, 0.1% Tween-20. The membranes were incubated with secondary antibodies, anti-mouse IgG conjugated HRP (1:4,000) (Promega), in blocking buffer and washed three times in PBS, 0.1% Tween-20. Immunoreactive bands were detected with an ECL kit (Amersham Biosciences) according to the manufacturer's instructions.
Gel mobility shift assays
Gel mobility shift assays were performed with modifications from a published procedure (11, 20) . The CG11 probe and anti-MBD2 antibody were gifts from Dr. Adrian Bird (Edinburgh, UK). The MCG11 probe, methylated CG11, was made by complete methylation of CG11 with SssI methylase (New England Biolabs). These probes were 32 P-end-labeled with gamma-32 P-ATP. Approximately 200 ng of recombinant protein was added and the mixture was incubated for 20 min at room temperature in binding buffer containing 20 mM HEPES, pH 7.9, 1 mM EDTA, 3 mM MgCl 2 , 2 mM dithiothreitol, 4% glycerol, 0.1% Triton X-100, and 250 ng of Escherichia coli DNA followed by a 30 min incubation on ice. 0.1 ng of probe and 5 g of HeLa cell nuclear extract were added in each binding reaction. The protein-DNA complexes were fractionated by electrophoresis on a 1.5% agarose gel in 0.5% TBE buffer and visualized by autoradiography.
Immunofluorescence studies 2.5 x 10 5 NIH3T3 or COS7 cells were cultured directly on cover-slips in a six-well plate. The transfection of these cells was achieved using Lipofectamine Plus reagent (Invitrogen) according to the manufacturer's instructions by using 2 g of plasmids. At 48 hours after transfection, cells were washed twice with PBS and then fixed in 4% formaldehyde for 5 min at room temperature. Then cells were permeabilized with 0.2% Triton X-100 in PBS for 10 min at room temperature and washed twice with PBS. After blocking for 1 hour at room temperature using 2.5% goat-serum (Sigma) and 0.2% Tween-20 in PBS, the cells were incubated with the primary antibody, mouse anti-c-myc IgG (5 g/ml) (Sigma), for 1 hour at room temperature in blocking buffer. The cells were washed three times with PBS containing 0.2% Tween-20 and were incubated with goat anti-mouse IgG coupled to Alexa 568 (Molecular Probes) for 1 hour in blocking buffer. The cells were washed again, stained with 0.25 g/ml of 4',6'-diamidino-2-phenylindole (DAPI) (Sigma) and mounted with 90% glycerol in PBS. Images were visualized with a confocal microscope (Zeiss LSM310) or an Olympus IX81 fluorescence microscope.
Chromatin immunoprecipitation
To test the methylation-dependent recruitment of proteins to transiently transfected reporter plasmids, AD293 cells were transfected with methylated and unmethylated pM1-luciferase constructs. Chromatin immunoprecipitation (ChIP) assays were carried out largely as described previously (31) . Immunoprecipitation was performed with 2 g of rabbit IgG (Santa Cruz), anti-MBD2 (Upstate Biotechnologies) or anti-HDAC2 (Abcam). PCR amplification was performed with DNA extracted from the immunoprecipitates, using 30 cycles of PCR. Primers used for PCR amplification of the CMV p r o m o t e r w e r e 5'-CAAGTCTCCACCCCATTGAC-3' (forward) and 5'-GAGGTCAAAACAGCGTGGAT-3' (reverse). For all ChIP experiments, varying amounts of input and precipitated DNA samples were tested in PCR reactions to determine the linear range of the reaction, and the data shown are from PCR reactions performed with a DNA amount in the linear range.
RESULTS
Among the family of human methyl-CpG binding domain proteins, MBD2 and MBD3 are the most closely related. We previously reported the identification of two mammalian homologues of 6 MBD2 and MBD3, which were named MBD3L1 and MBD3L2 (30) . Figure 1 shows the homology between MBD2, MBD3, MBD3L1 and MBD3L2. Both MBD3L1 and MBD3L2 lack the MBD domain. All four proteins contain a coiled-coil domain at the C-terminus (Fig. 1A) . The longer form of MBD2, MBD2a, contains an N-terminal glycine-arginine-rich repeat, which is absent from the shorter form, MBD2b. MBD2t is a truncated testis-specific variant of MBD2.
We have focused here on the characterization of MBD3L2. Expression analysis by Northern blotting showed that the gene is expressed ubiquitously in human tissues (Fig. 2) . This is in contrast to MBD3L1, which is expressed predominantly in testis, specifically in postmeiotic haploid cells (30) .
Since MBD3L1 has been shown to act as a transcriptional repressor (30), we analyzed the effects of MBD3L2 on the transcription of a reporter gene (Fig. 3) . We conducted assays in which the MBD3L2 protein was tethered to a promoter via a fused GAL4 DNA binding domain. Two promoters having five or six tandem GAL4 DNA binding sites were chosen, the alpha globin promoter and the VHL gene promoter (Fig. 3) . These promoters drive the expression of a luciferase reporter gene. AD293 cells were cotransfected with the MBD3L2-GAL4 fusion constructs and the luciferase reporter plasmids. In these assays, the MBD3L2 construct inhibited expression of the alpha globin promoter even stronger than the MBD2b construct (more than 80% inhibition) (Fig. 3B) . With the V H L promoter, MBD3L2 caused a 40% inhibition of promoter activity (Fig. 3D) . Three parts of the MBD3L2 gene were fused to the GAL4 DNA binding domain. The N-terminal portion of the protein (amino acids 1 to 72) showed the strongest inhibition, but also the central part of the protein (amino acids 70 to 135) and the C-terminal portion (amino acids 134 to 204) inhibited reporter activity (Fig. 3B) indicating that this protein has several independent transcriptional repression domains. We next investigated if transcriptional repression by MBD3L2 could be released by the histone deacetylase inhibitor trichostatin A (TSA) (Fig. 3C,D) . TSA did not relieve transcriptional repression of the alpha-globin promoter and there was an apparent further repression of this promoter by TSA. This effect of TSA may be explained by the fact that TSA affects acetylation on a global scale and indirect effects (e.g. activation of an additional repressor) cannot be excluded. On the other hand, TSA relieved repression of the VHL promoter indicating that the repressive effect imposed by MBD3L2 on this promoter is associated with histone deacetylation.
The presence of coiled coil domains in MBD2, MBD3, and MBD3L2 suggested that these proteins may have the potential to heterodimerize through this type of motif, which is often involved in protein-protein interactions. In order to test interactions between these proteins, we carried out a yeast two-hybrid analysis (Fig. 4A) . The sequences were cloned into the GAL4-activation domain and GAL4-DNA binding domain vectors, respectively. For MBD2, we used the longer and shorter forms, MBD2a and MBD2b, as well as the testis-specific variant, MBD2t. Two-hybrid interactions were observed between MBD2a/b and MBD3. An interaction between MBD2 and MBD3 has been reported previously (32) and we confirmed these findings. Binding between MBD2 and MBD3 may form the basis for the recruitment of a larger transcriptional repressor complex, NuRD/MeCP1, containing MBD3 to methylated DNA, since mammalian MBD3 alone cannot bind to CpG-methylated DNA (1,8,21 ). When MBD3L2 was present in the activation domain vector, it interacted with MBD2b and MBD3. However, when MBD3L2 was present in the DNA binding domain vector, an interaction was observed only with MBD3 (Fig.4A) .
Since the two-hybrid data suggested that MBD3 is the most likely binding partner of MBD3L2, we tested if MBD3 and MBD3L2 can interact in vitro (Fig. 4B,C) . Glutathione-S-transferase-(GST)-tagged MBD3L2-and MBD3-vectors and the corresponding deletion constructs were prepared and the proteins were expressed in E. coli. After binding of these proteins to glutathione-agarose beads, they were incubated with recombinant Histagged MBD3 or MBD2b or FLAG-tagged MBD3L2. A clear interaction between MBD3 and MBD3L2 was observed with the full-length proteins. MBD2 interacted with MBD3L2 in vitro only very weakly ( Fig. 4B ; compare to percent 7 input) but interacted strongly with MBD3 (Fig.  4B) . For binding to MBD3, a part of MBD3L2 was required that included amino acids spanning the N-terminal part of the protein, as significant binding was observed when construct 1-89 was used (Fig. 4B) . Binding of MBD3L2 to MBD3 required a part in the N-terminal region (amino acids 60-80) of MBD3 since binding was observed with fragments 1-80 and 60-120. This region was partially overlapping with the region of MBD3 required to bind to MBD2b (amino acids 1-80) although binding to the 60-120 fragment was not observed (Fig. 4C) . Surprisingly, the data indicate that the coiled-coil domains present in both MBD3 and MBD3L2 (Fig. 1) were not required for the interaction.
To further corroborate the observed interactions between MBD3L2 and MBD3, we analyzed the intracellular localization of the tagged proteins by immunofluorescence microscopy in COS7 cells (Fig. 5 ). We also tested for possible co-localization of MBD3L2 and MBD2. All three proteins displayed a speckled nuclear localization pattern. MBD3L2 and MBD2a or MBD3L2 and MBD2b did not co-localize significantly. However, we observed an at least partial co-localization of MBD3L2 and MBD3 (Fig. 5A ). There was colocalization of MBD2a but not of MBD3L2 with DAPI-bright areas (Fig. 5B) . In mouse cells, approximately 50% of all 5-methylcytosine is concentrated in major satellite DNA, which is organized in foci of constitutive heterochromatin and stains brightly with Hoechst 33258 or DAPI (33). These sequences have been shown to attract several of the methyl-CpG binding proteins in transfected cells (8) . In order to determine the localization of GFP-tagged MBD3L2 in mouse cells, we transfected the construct into NIH3T3 cells. DAPI staining indicated the position of pericentromeric heterochromatin. There was no co-localization of MBD3L2 and the highly methylated major satellite DNA in mouse cells (Fig. 5C ).
The MBD3 protein has been shown to be a component of a larger complex, termed Mi2/NuRD, which is involved in nucleosome remodeling and transcriptional repression, and contains histone deacetylases (18, 20, 26, 27) . To determine if MBD3L2 associates with MBD3 in vivo and is part of this complex, we transfected a GST-tagged MBD3L2 construct into AD293 cells and carried out GST-pulldown experiments (Fig.  6 ). Western blot analysis was used to determine the possible association of several endogenous proteins with GST-MBD3L2. We found that MBD2 and Sin3 were clearly not associated with MBD3L2. The proteins specifically retained by GST-MBD3L2 resins were Mi2, MTA1 (but not MTA2), p66 (only the upper band was enriched), HDAC1, HDAC2, RbAP46, RbAP48, and MBD3 (Fig. 6) . The data confirm that MBD3L2 and MBD3 interact in vivo. The interaction of MBD3L2 with Mi2, MTA1, p66, HDAC1, HDAC2, RbAP46, RbAP48, and MBD3, indicates that MBD3L2 is associated with the NuRD complex.
The NuRD complex can be recruited to CpGmethylated DNA by interaction of the complex with MBD2 (11, 20, 29) . Although NuRD does contain the methyl-CpG binding protein MBD3, it is unlikely that these components alone can be involved in repression of methylated DNA inasmuch mammalian MBD3 is incapable of binding to methylated DNA (1,8,21 ). However, by binding to MBD2, presumably through heterodimerization of MBD2 and MBD3, the NuRD complex may be recruited to methylated DNA (11, 20, 29) . The complex of MBD2 and NuRD has been referred to as MeCP1, a large methylated DNA binding complex that was initially identified 16 years ago (19). MBD3L2 does not contain a methyl-CpG binding domain and we confirmed by gel mobility shift assays that the recombinant protein cannot bind to a CpG methylated DNA probe (Fig. 7A) . Also, MBD3 alone or a complex of MBD3 and MBD3L2 did not bind to methylated DNA in vitro. We then investigated if MBD3L2 has an effect on the MeCP1 complex. MeCP1 has been routinely characterized as a complex from HeLa cell nuclear extracts that binds specifically to a methylated probe (mCG11) (11, 19, 20, 29) . We were able to resolve the MeCP1 complex into three main bands using a gel shift assay (Fig. 7B) . None of the three upper bands were formed with the unmethylated CG11 probe (data not shown). Using an antibody against MBD2, we show that MBD2 is a component of the upper MeCP1 complex as indicated by a supershifted band (compare lanes 3 8 and 4, Fig. 7B ). The lower two bands were less affected by the MBD2 antibody, presumably because the epitopes are not accessible or they do not contain MBD2. We added recombinant MBD3L2 to the mobility shift reactions (Fig. 7B) . When MBD3L2 was added, the MeCP1 band migrating at the upper position almost completely disappeared. Addition of recombinant MBD3 to these reactions was without effect (data not shown). This data further indicates that MBD3L2 can interact with the MeCP1/NuRD complex and is able to displace one form of MeCP1 that contains MBD2 from methylated DNA.
To test the possible interplay between MBD2 and MBD3L2 in transcriptional repression, we carried out transcriptional repression assays. Using the GAL4 fusion protein system and the alpha-globin promoter, we chose conditions in which these two proteins produce about 50% repression of the reporter gene (Fig. 8) . When repression was induced by GAL4-DB-MBD2b, co-transfection of MBD3L2 relieved repression in a dose-dependent manner. When repression was induced by GAL4-DB-MBD3L2, co-transfection of MBD2b relieved repression in a similar way (Fig. 8) . These data suggest that the MBD3L2 and MBD2 proteins can mutually relieve repression in this system and that they may compete for the same binding partner (e.g., MBD3) in the repression process.
Since the repression assay with GAL4 DNA binding domain fusions represents a somewhat artificial situation, we conducted repression assays with a CpG-methylated reporter gene. We used the firefly luciferase gene under control of the CMV promoter. When this construct was methylated at CpG sites by using S s sI DNA methylase, the expression of the reporter gene was strongly (~11-fold) reduced at 48 hours after transfection (Fig. 9 , compare panels A and B). When an MBD2b expression vector was co-transfected with the methylated plasmid, its activity was further reduced (Fig. 9A) indicating that MBD2b can mediate repression from a CpG-methylated promoter. No effect of MBD2b co-expression was observed with an unmethylated promoter (Fig.  9B) . However, the repression of the methylated promoter was efficiently relieved when MBD3L2 was co-transfected (Fig. 9A) . This data suggests that MBD3L2 can compete with MBD2b and can alleviate MBD2b repression at methylated promoters. The presence of MBD2 and HDAC2 on the methylated but not the unmethylated CMV promoter was confirmed by chromatin immunoprecipitation (Fig. 9C) .
DISCUSSION
We have characterized the MBD3L2 protein, a homologue of MBD2 and MBD3. Unlike its closest homologue, MBD3L1, which is expressed predominantly in postmeiotic male germ cells (30) , MBD3L2 is more widely expressed. We show that the MBD3L2 protein can act as a transcriptional repressor when tethered to a promoter and is associated with components of the NuRD complex. This complex contains histone deacetylase activity. MBD3L2 repression was sensitive to inhibitors of histone deacetylases but this effect was promoter-dependent. The binding of MBD3L2 to the NuRD complex is most likely mediated through its interaction with the NuRD component MBD3. The interaction between MBD3L2 and MBD3 was confirmed by yeast twohybrid assays, by in vitro binding assays, by in vivo pull-down assays, and by co-localization studies. On the other hand, MBD3L1 interacts preferentially with MBD2 rather than MBD3, and MBD3L1 and MBD3 do not co-localize or interact in vivo (34) . Thus, a picture emerges in which several hetero-oligomeric (and possibly homooligomeric) complexes can form between the four related proteins MBD2, MBD3, MBD3L1, and MBD3L2. The functional significance of each of these interactions will need to be investigated in more detail. All four proteins operate as transcriptional repressors in assays where they are recruited to promoters through heterologous (GAL4) DNA binding domains. How these proteins are recruited in vivo to promoters has not yet been determined, except for MBD2, for which its association with CpG methylated DNA has been shown to result in transcriptional repression. MBD3, as a component of the NuRD complex, also is apparently involved in repression of methylated DNA. However, this can only be one of the functions of MBD3, since MBD2 and MBD3 appear to have different characteristics. The phenotype of knockout mice for the two proteins is very different. Mbd3 -/-mice die during 9 early embryogenesis, whereas Mbd2 -/-mice are viable and fertile (15) . Also, the nuclear localization of MBD2 and MBD3 is quite different. While MBD2 is preferentially associated with methyl-CpG-rich major satellite DNA (pericentromeric heterochromatin) in mouse cells (8) , the majority of MBD3 does not localize to these sites. Similar to MBD3, its binding partner MBD3L2 also does not co-localize with pericentromeric heterochromatin (Fig. 5C) . One possibility is that the MBD3L2/NuRD complex is involved in DNA methylation-independent transcriptional repression. Then, this complex would need to be recruited to promoters by means other than CpG methylation, perhaps through interaction with sequence-specific transcription factors.
It is also of note that we did not find evidence for specific binding of the MTA2 protein in the MBD3L2-pulled down fractions. Instead, a specific association with MTA1 was observed. It is becoming recognized that there are different subforms of the NuRD complex (35) . Every subunit of this complex presents heterogeneity at the protein or gene level. In particular, the reported complexes differ in their composition with respect to whether they contain MTA1 or MTA2 (20, 25, 36) . Three separate genes encode the MTA family proteins in mammals. MTA1 was initially described as a gene highly expressed in tumor cell types with invasive and metastatic growth properties (37). MTA2 has not yet been linked with cellular transformation. It has been suggested that MTA2 may function more generally in transcriptional regulation, while MTA1 and MTA3 may play a role in estrogen receptor-dependent transcription (35, 38) . Thus, specific NuRD complexes may differ with respect to whether they contain MBD3L2 or not.
We have shown that MBD3L2 can displace a form of the MeCP1 complex from CpG-methylated DNA (Fig. 7B) , can relieve repression mediated by MBD2b tethered to a promoter (Fig. 8) or relieve MBD2 repression acting on a CpG-methylated promoter (Fig. 9) . Both MBD3L2 and MBD2b can bind to the N-terminal portion of the MBD3 protein (Fig. 4) . This data combined would suggest a model in which the NuRD complex, through its MBD3 subunit, may interact either with MBD2 or with MBD3L2 (Fig. 10) . The two complexes may co-exist in cells with the MBD2/NuRD complex involved in methylationmediated repression and the MBD3L2/NuRD complex involved in methylation-independent repression or no repression at all. The association of MBD3L2 with the NuRD complex may determine the nuclear localization pattern of this form of the complex since MBD2 (presumably also associated with NuRD components) and MBD3/MBD3L2 are localized clearly differently in subnuclear compartments (Fig. 5) . Thus, MBD3L2 has the capacity to modulate expression of methylation-silenced genes. In future work, the gene targets for any MBD3L2-induced modulation of transcription as well as the mechanisms of these pathways will need to be determined on a larger scale by using, for example, expression microarrays. A potential role of MBD3L2 in converting methylation-dependent gene silencing into methylation-independent silencing will also need to be investigated. Our data are consistent with a role of MBD3L2 as a transcriptional modulator that can interchange with MBD2 as a component of the NuRD complex and has the potential to recruit the MeCP1 complex away from methylated DNA, thus resulting in gene reactivation.
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